Clostridium Difficile Infection in Children
A Review
Elena Borali
Paediatrics Division, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Search for more papers by this authorCorresponding Author
Costantino De Giacomo
Paediatrics Division, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Address correspondence and reprint requests to Costantino De Giacomo, MD, Paediatrics Division, ASST Grande Ospedale Metropolitano Niguarda, P.le Ospedale Maggiore 3, 20162 Milan, Italy (e-mail: [email protected]).Search for more papers by this authorElena Borali
Paediatrics Division, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Search for more papers by this authorCorresponding Author
Costantino De Giacomo
Paediatrics Division, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Address correspondence and reprint requests to Costantino De Giacomo, MD, Paediatrics Division, ASST Grande Ospedale Metropolitano Niguarda, P.le Ospedale Maggiore 3, 20162 Milan, Italy (e-mail: [email protected]).Search for more papers by this authorwww.clinicaltrials.gov registration number: NCT02218372.
The authors report no conflicts of interest.
ABSTRACT
Clostridium difficile is a sporogenic, anaerobic, Gram-positive, emerging enteric pathogen. It represents the most common cause of health care-associated diarrhoea in the United States, with significantly associated morbidity, mortality, and health care costs. Historically regarded as a little more than an innocent coloniser bystander of the gastrointestinal tract of children, C difficile has increasingly demonstrated its behaviour as a true pathogen in the paediatric age groups. This organism may be responsible for a broad spectrum of diseases in children, ranging from self-limiting secretory diarrhoea to life-threatening conditions, such as pseudomembranous colitis, toxic megacolon, intestinal perforation, and septic shock. The incidence and severity of C difficile infection are, however, not completely understood in this population. In particular, although asymptomatic carriage remains high among infants, the clinical significance of detecting C difficile in children aged 1 to 3 years is not fully understood. Moreover, recent epidemiological surveillance has demonstrated a rise in the incidence of C difficile infection, particularly in the community and in low-risk settings. Interestingly, such cases may not show the disease pattern to be associated with typical risk factors, such as recent exposure to antimicrobial drugs or on-going contacts with the health care system.
The purpose of the present review is to present the features of C difficile infection that are unique to paediatric patients and to update paediatricians on information and recommendations regarding C difficile infection in children.
REFERENCES
- 1.Hall IC, O’Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935; 49: 390–402.
- 2.Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526–536.
- 3.Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infection in acute care hospital. Infect Control Hosp Epidemiol 2008; 29: S81–S89.
- 4.Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8: 17–26.
- 5.Hourigan SK, Oliva-Hemker M. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease. Dig Dis Sci 2014; 59: 2222–2227.
- 6.Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758–764.
- 7.Sammons JS, Toltzis P. Recent trends in the epidemiology and treatment of C. difficile infection in children. Curr Opin Pediatr 2013; 25: 116–121.
- 8.Crobach MJT, Dekkers OM, Wilcox MH, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15: 1053–1066.
- 9.Loo VG. Environmental interventions to control Clostridium difficile. Infect Dis Clin North Am 2015; 29: 83–91.
- 10. Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012; 61: 157–162.
- 11.Loo VG, Poirier L, Miller M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442–2449.
- 12.Morinville V, McDonalds J. Clostridium difficile-associated diarrhea in 200 Canadian children. Can J Gastroenterol 2005; 19: 497–501.
- 13.Schutze GE, Willoughby RE. Committee on Infectious Disease, American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics 2013; 131: 196–200.
- 14.Borali E, Ortisi G, Moretti C, et al. Community-acquired Clostridium difficile infection in children: a retrospective study. Dig Liver Dis 2015; 47: 842–846.
- 15.Tschudin-Sutter S, Tamma PD, Milstone AM, et al. Predictors of first recurrence of Clostridium difficile infections in children. Pediatr Infect Dis J 2014; 33: 414–416.
- 16.Wendt JM, Cohen JA, Mu Y, et al. Clostridium difficile infection among children across diverse US geographic locations. Pediatrics 2014; 133: 651–658.
- 17.Cohen SH, Gerding DN, Johnson S, et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431–455.
- 18.Zilberberg MD, Shorr AF, Kollef MH. Increased in Clostridium difficile-related hospitalizations among infants in the Unites States, 2000-2005. Pediatr Infect Dis J 2008; 27: 1111–1113.
- 19.McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140–145.
- 20.Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13: 1417–1419.
- 21.Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011; 165: 451–457.
- 22.Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122: 1266–1270.
- 23.Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children United States, 1997-2006. Emerg Infect Dis 2010; 16: 604–609.
- 24.Khalaf N, Crews JD, DuPont HL, et al. Clostridium difficile: an emerging pathogen in children. Discov Med 2012; 14: 105–113.
- 25.Pant C, Deshpande A, Gilroy R, et al. Rising incidence of Clostridium difficile related discharges among hospitalized children in the United States. Infect Control Hosp Epidemiol 2015; 37: 104–106.
- 26. Centers for Disease Control and Prevention. Surveillance for community associated Clostridium difficile--Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008; 57: 340–343.
- 27.Sandora TJ, Fung M, Flaherty K, et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011; 30: 580–584.
- 28.Benson L, Song X, Campos J, et al. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007; 28: 1233–1235.
- 29.Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079–1084.
- 30.Toltzis P, Kim J, Dul M, et al. Presence of the epidemic North American Pulsed Field type 1 Clostridium difficile strain in hospitalized children. J Pediatr 2009; 154: 607–608.
- 31.Spigaglia P, Barbanti F, Castagnola E, et al. Clostridium difficile infection (CDI) in children due to hypervirulent strains PCR-ribotype 027: an emblematic report of two cases. Anaerobe 2015; 36: 91–93.
- 32.Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63–73.
- 33.Hensgens MP, Goorhuis A, Notermans DW, et al. Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands. Euro Surveill 2009; 14: 1–3.
10.2807/ese.14.45.19402-en Google Scholar
- 34.Wilcox MH, Shetty N, Fawley WN, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping based surveillance scheme in England. Clin Infect Dis 2012; 55: 1056–1063.
- 35.Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 292: 1115–1118.
- 36.Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635–1638.
- 37.Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011; 121: 2126–2132.
- 38.Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol 2007; 5: e177.
- 39.Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197: 435–438.
- 40.Jangi S, Lamont JT. Asympomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterolog Nutr 2010; 51: 2–7.
- 41.Matsuki S, Ozaki E, Shozu M, et al. Colonization by Clostridium difficile of neonates in a hospital, and infants and children in three day-care facilities of Kanazawa, Japan. Int Microbiol 2005; 8: 43–48.
- 42.Penders J, Vink C, Driessen C, et al. Quantification of Bifidobacterium spp., Escherichia coli and Clostridium difficile in faecal samples of breast-fed and formula-fed infants by real-time PCR. FEMS Microbiol Lett 2005; 243: 141–147.
- 43.Delmée M, Verellen G, Avesani V, et al. Clostridium difficile in neonates: serogrouping and epidemiology. Eur J Pediatr 1988; 147: 36–40.
- 44.Monot M, Eckert C, Lemire A, et al. Clostridium difficile: new Insights into the evolution of the pathogenicity locus. Sci Rep 2015; 5: 15023.
- 45.Govind R, Dupuy B. Secretion of Clostridium difficile toxins A and B requires the holin-like protein TcdE. PLoS Pathog 2012; 8: e1002727.
- 46.Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 2007; 64: 1274–1288.
- 47.Carter GP, Lyras D, Allen DL, et al. Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J Bacteriol 2007; 189: 7290–7301.
- 48.Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med 2008; 359: 1932–1940.
- 49.Cairns MD, Stabler RA, Shetty N, et al. The continually evolving Clostridium difficile species. Future Microbiol 2012; 7: 945–957.
- 50.Pothoulakis C, Lamont JT. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001; 280: G178–G183.
- 51.Viscidi R, Laughon BE, Yolken R, et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1983; 148: 93–100.
- 52.Bryant K, McDonald LC. Clostridium difficile infections in children. Pediatr Infect Dis J 2009; 28: 145–146.
- 53.Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe Clostridium difficile infection in children. Pediatr Infect Dis J 2012; 31: 134–138.
- 54.Samady W, Pong A, Fisher E. Risk factors for the development of Clostridium difficile infection in hospitalized children. Curr Opin Pediatr 2014; 26: 568–572.
- 55.Duleba K, Pawlowska M, Wietlicka-Piszcz M. Clostridium difficile infection in children hospitalized due to diarrhea. Eur J Clin Microbiol Infect Dis 2014; 33: 201–209.
- 56.Schwartz KL, Darwish I, Richardson SE, et al. Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study. BMC Pediatr 2014; 14: 28.
- 57.Samady W, Bush R, Pong A, et al. Predictors of Clostridium difficile infections in hospitalized children. J Hosp Med 2014; 9: 94–98.
- 58.Owens RC Jr, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 (suppl 1): S19–S31.
- 59.Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107: 1001–1010.
- 60.Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-Analysis. Am J Gastroenterol 2012; 107: 1011–1019.
- 61.Jimenez J, Drees M, Loveridge-Lenza B, et al. Exposure to gastric acid-suppression therapy is associated with healthcare-associated and community-associated C. difficile infection in children. J Pediatr Gastroenterol Nutr 2015; 61: 208–211.
- 62.Hassell E. Over-prescription of acid-suppressing medications in infants: how it came about, why it's wrong, and what to do about it. J Pediatr 2012; 160: 193–198.
- 63.Mc Laughlin D, Friedmacher F, Puri P. The impact of Clostridium difficile on paediatric surgical practice: a systematic review. Pediatr Surg Int 2014; 30: 853–859.
- 64.Martinelli M, Strisciuglio C, Veres G, et al. Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study. Inflamm Bowel Dis 2014; 20: 2219–2225.
- 65.De Graaf H, Pai S, Burns DA, et al. Co-infection as a confounder for the role of Clostridium difficile infection in children with diarrhea: a summary of the literature. Eur J Clin Microbiol Infect Dis 2015; 34: 1281–1287.
- 66.Elliott B, Chang BJ, Golledge CL, et al. Clostridium difficile-associated diarrhea. Intern Med J 2007; 37: 561–568.
- 67.Gogate A, De A, Nanivandekar R, et al. Diagnostic role of stool culture & toxin detection in antibiotic associated diarrhea due to Clostridium difficile in children. Indian J Med Res 2005; 122: 518–524.
- 68.Pai S, Aliyu SH, Enoch DA, et al. Five years’ experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PLoS One 2012; 7: e51728.
- 69.Nicholson MR, Thomsen IP, Slaughter JC, et al. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr 2015; 60: 18–22.
- 70.Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis 2013; 56: 1401–1406.
- 71.Kociolek LK, Palac HL, Patel SJ, et al. Risk factors for recurrent Clostridium difficile infection in children: a nested case-control study. J Pediatr 2015; 167: 384–389.
- 72.Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478–498.
- 73.Planche T, Aghaizu A, Holliman R, et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008; 8: 777–784.
- 74.Fenner L, Widmer AF, Goy G, et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008; 46: 328–330.
- 75.Peterson LR, Manson RU, Paule SM, et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis 2007; 45: 1152–1160.
- 76.Luna RA, Boyanton BL, Mehta S, et al. Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital. J Clin Microbiol 2011; 49: 851–857.
- 77. Department of Health (2012). Updated guidance on the diagnosis and reporting of Clostridium difficile. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215135/dh_133016.pdf. Accessed September 1, 2015.
- 78.Pickering L, Baker C, Bernstein H, et al. Clostridium difficile. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012: 285–7.
- 79.Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302–307.
- 80.Vardakas KZ, Polyzos KA, Patouni K, et al. Treatment failure and recurrence of Clostridium difficile infections following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012; 40: 1–8.
- 81.Vaishnavi C. Fidaxomicin--the new drug for Clostridium difficile infection. Indian J Med Res 141 2015; 141: 398–407.
- 82.Smeltzer S, Hassoun A. Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child. J Antimicrob Chemother 2013; 68: 1688–1689.
- 83.Ooi CY, Dilley AV, Day AS. Saccharomyces boulardii in a child with recurrent Clostridium difficile. Pediatr Int 2009; 51: 156–158.
- 84.Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013; 29: 79–84.
- 85.Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994–1002.
- 86.Russell G, Kaplan J, Ferraro M, et al. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics 2010; 126: e239–e242.
- 87.Kronman MP, Nielson HJ, Adler AL, et al. Fecal microbiota transplantation via nasogastric tube for recurrent Clostridium difficile infection in pediatric patients. J Pediatr Gastroenterol Nutr 2015; 60: 23–26.
- 88.Kahn SA, Young S, Rubin DT. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol 2012; 107: 1930–1931.
- 89.Russell G, Kaplan JL, Youngster I, et al. Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 58: 588–592.
- 90.Pierog A, Mencin A, Reilly NR. Fecal microbiota transplantation in children with recurrent Clostridium difficile infection. Pediatr Infect Dis J 2014; 33: 1198–1200.
- 91.Zipursky JS, Sidorsky TI, Freedman CA, et al. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012; 55: 1652–1658.
- 92.Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197–205.
- 93.Foglia G, Shah S, Luxemburger C, et al. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012; 30: 4307–4309.
- 94.Huang JH, Wu CW, Lien SP, et al. Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci 2015; 22: 65.
- 95.Pant C, Deshpande A, Altaf MA, et al. Clostridium difficile infection in children: a comprehensive review. Curr Med Res Opin 2013; 29: 967–984.
- 96.McGlone SM, Bailey RR, Zimmer SM, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012; 18: 282–289.
- 97.Muto CA, Blank MK, Marsh JW, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 2007; 45: 1266–1273.
- 98.Leffler DA, Lamont JT. Clostridium difficile Infection. N Engl J Med 2015; 373: 287–288.